Crohn’s disease and ulcerative colitis are often treated with thiopurines, although some patients have adverse drug reactions to this treatment. Specifically, 7 per cent of patients develop ‘bone marrow suppression’ in response to this treatment plan. Researchers believe they have found that a mutation in the NUDT15 gene is responsible for this adverse reaction. Once a predictive test is developed for this mutation, patients will be able to have a blood test before being prescribed medication and discover if they will have an adverse reaction.
Source: Science Daily
Read more: http://ow.ly/7U0T30nV1ls